Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure

What Was Tested

The paper reports a study of BNP (Nesiritide), published as a randomized controlled trial.

To observe the changes of serum heart-type fatty acid-binding protein (h-FABP) and brain natriuretic peptide (BNP) in children with chronic heart failure (CHF) and evaluate the effects of carvedilol.

Who Took Part

The abstract describes 36 patients taking part.

PubMed indexes the participants as infants, young children and children, both men and women.

A total of 36 patients with CHF, including 17 of endocardial fibroelastosis and 19 of dilated cardiomyopathy, were enrolled and were randomly divided into a carvedilol treatment group (group A) and a conventional treatment group (group B).

Group A (n = 16) was treated with carvedilol and conventional treatment and group B (n = 20) was managed with conventional treatment only.

How the Study Was Run

The researchers set it up as a randomized study.

The patients were allocated by chance, so the BNP (Nesiritide) group and the comparison group should start out alike.

Thirty healthy children were enrolled as controls.

What Was Measured

PubMed files the paper under topics including Adrenergic beta-Antagonists, Age Factors, Biomarkers, Carbazoles, Carvedilol, China and Chronic Disease.

What This Means in Plain Language

The paper is a randomized study of BNP (Nesiritide) in 36 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (Journal of cardiovascular pharmacology), a journal based in United States.

More context: the BNP (Nesiritide) compound page, all human trials.